普罗布考联合阿托伐他汀治疗急性脑梗死的临床研究

目的：探究普罗布考联合阿托伐他汀治疗急性脑梗死的临床效果。方法选取2011年5月—2013年5月首都医科大学附属北京友谊医院收治的急性脑梗死患者80例，随机分为治疗组和对照组，每组40例。对照组患者在常规治疗基础上加服阿托伐他汀片，1片/次，1次/d。治疗组在对照组用药的基础上加用普罗布考片，4片/次，2次/d。两组均连续治疗6个月。比较两组治疗前后相关生化指标、血脂水平、颈动脉粥样硬化斑块面积、颈动脉内膜中膜厚度。结果治疗后，两组患者超敏C反应蛋白、氧化低密度脂蛋白（ox-LDL）、基质金属蛋白酶-2（MMP-2）、MMP-9、NIHSS评分均较治疗前显著降低，两组血清脂联素比治疗前增加，同组治疗前后差异有统计学意义（P＜0.05）；治疗后，治疗组这些指标的改善程度优于对照组，两组比较差异有统计学意义（P＜0.05）。治疗后，两组总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平均较治疗前显著降低，且高密度脂蛋白胆固醇（HDL-C）较治疗前显著升高，同组治疗前后比较差异有统计学意义（P＜0.05）；治疗后，治疗组TC、TG、LDL-C水平低于对照组，两组比较差异有统计学意义（P＜0.05）。两组患者治疗后的斑块面积和内膜中膜厚度均较治疗前显著降低，同组治疗前后差异有统计学意义（P＜0.05）；治疗后，治疗组这两个指标均低于对照组，两组比较差异有统计学意义（P＜0.05）。结论普罗布考联合阿托伐他汀治疗急性脑梗死患者具有较好的临床疗效，可降低患者血脂水平，抑制动脉粥样硬化斑块的发展，值得临床推广应用。

Clinical study on probucol combined with atorvastatin in treatment of acute cerebral infarction

Objective To investigate the clinical effect of probucol combined with atorvastatin in treatment of acute cerebral infarction. Methods The patients with acute cerebral infarction (80 cases) of Beijing Friendship Hospital Affiliated to Capital Medical Universityfrom May 2011 to May 2013 were randomly divided into treatment and control groups, and each group had 40 cases. The patients in the control group were po administered with Atorvastatin Tablets on the basis of conventional treatment, one tablet/time, once daily. The patients in the treatment group were po administered with Probucol Tablets at the basis of the control group, 4 tablets/time, twice daily. The patients in two groups were treated for 6 months. The related biochemical indexes, blood lipid levels, area of carotid atherosclerotic plaque, and film thickness of the carotid artery intima in two groups before and after treatment were compared. Results After treatment, hypersensitive C reactive protein, ox-LDL, MMP-2, MMP-9, and NIHSS score in two groups were significantly reduced, while serum level of adiponectin increased, and the difference was statistically significant in the same group before and after treatment (P < 0.05). After treatment, these indicators in the treatment group improved better than those of control group, and there were differences between the two groups (P < 0.05). After treatment, TC, TG, and LDL-C in two groups were significantly reduced, while HDL-C increased, and the difference was statistically significant in the same group before and after treatment (P < 0.05). After treatment, TC, TG, and LDL-C in treatment group were lower than those in the control group, and there were differences between the two groups (P < 0.05). After treatment, the area of carotid atherosclerotic plaque and film thickness of the carotid artery intima in two groups were significantly reduced, and the difference was statistically significant in the same group before and after treatment (P < 0.05). After treatment, the two indicators in the treatment group were lower than those in the control group, and there were differences between the two groups (P < 0.05). Conclusion Probucol combined with atorvastatin has the good clinical effect in treatment of acute cerebral infarction, and can decrease blood lipid level, while can inhibit the development of atherosclerotic plaque, which is worth clinical promotion.